Affiliation: | aDepartment of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, 1008 West Hazelwood Drive, Urbana, IL 61801, USA bDepartment of Biochemistry, University of Illinois at Urbana-Champaign, 600 South Mathews Avenue, Urbana, IL 61801, USA cHoward Hughes Medical Institute, Yale University, 300 Ceder Street, TAC S569, New Haven, CT 06520, USA dDepartment of Pathology, School of Medicine, Neuroscience Program, University of Illinois at Urbana-Champaign, 506 South Mathews Avenue, Urbana, IL 61801, USA |
Abstract: | Transforming growth factor β1 (TGFβ1) is a pleiotropic cytokine, capable of exerting diverse biologic effects. Despite its central role in multiple immune activities, the molecular signals responsible for shaping TGFβ1's immunologic properties remain poorly elucidated. We report that costimulatory strength acts as a molecular switch, which influences the differential effects of TGFβ1 on the effector and regulatory development of naïve CD8+ lymphocytes. At low costimulation, TGFβ1 inhibits proliferation of CD8+ lymphocytes and cytokine secretion, but at high costimulation the response to TGFβ1 is quite different. High costimulation combined with TGFβ1 generates CD8+CD25+ T lymphocytes which maintain robust proliferative and survival capacity in the presence of low IL-2 concentrations. Furthermore, under these conditions, a subpopulation of CD8+ T lymphocytes is generated that express Foxp3, secrete IL-10, and inhibit naïve T lymphocyte proliferation via a contact-dependent mechanism. The adoptive transfer of these CD8+CD25+Foxp3+ T cells into mice inoculated intravenously with B16F10 melanoma appears to accelerate tumor progression as reflected by an increase in the number of pulmonary metastatic tumor foci. These findings indicate that costimulatory strength may act as a molecular switch in the generation of CD8+ T cells which possess a regulatory phenotype and the capacity to reduce antitumor immune responses within tumor-bearing mice. |